In the past five years, a number of instruments have been made available for the treatment of moderate to advanced Alzheimer’s disease (AD). The first installment of this two-part article focuses on the use of cholinsterase inhibitors and memantine in the treatment of moderate to severe AD. Look for the second part of this article in the next issue of The Canadian Alzheimer Disease Review
by Serge Gauthier, MD, FRCPC
Dr. Gauthier is a Professor of Neurology and Neurosurgery, Psychiatry and Medicine, McGill
University, McGill Centre for Studies in Aging, Montreal, Quebec.